Copy link
Export CSV
Cite this view
HANK Price Transparency. (n.d.).
Yttrium 90 ibritumomab tiuxetan (HCPCS C1083) by State .
PPMan price-transparency data, derived from CMS-required hospital MRFs.
Retrieved July 1, 2026 , from http://ppman.hank.ai/transparency/procedure/C1083/by-state?code_type=HCPCS
“Yttrium 90 ibritumomab tiuxetan (HCPCS C1083) by State.” HANK Price Transparency ,
http://ppman.hank.ai/transparency/procedure/C1083/by-state?code_type=HCPCS. Accessed
July 1, 2026 .
“Yttrium 90 ibritumomab tiuxetan (HCPCS C1083) by State,” HANK Price Transparency ,
accessed July 1, 2026 ,
http://ppman.hank.ai/transparency/procedure/C1083/by-state?code_type=HCPCS.
Source: PPMan price-transparency data, derived from CMS-required hospital
machine-readable files (45 CFR 180). See
methodology .
Print / Save PDF
HCPCS · across United States
C1083 — Yttrium 90 Ibritumomab Tiuxetan
State-by-state median negotiated rates. Lower bars are cheaper states; the
range bar shows the IQR (25th to 75th percentile within each state).
$20,788
National median
$20,788 – $21,411
IQR (p25 – p75)
8
hospitals filing
3
states
Median negotiated rate, by state
Ranked by typical (median) negotiated price. Hover for state-level IQR.
Median negotiated rate by state for C1083 (HCPCS), with interquartile range
State Median p25 p75
NY $20,788 $20,788 $21,411
WV $95 $95 $95
PA $40 $40 $40